800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis

view all Clinical Trials

Overview

Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part. The purpose of this study is to find out how well BI 1839100 helps reduce coughing in people with IPF or PPF.

Clinical Trial Information

Protocol

TIRB#: 31970

Phase

2

Condition(s)

Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF), Pulmonary Fibrosis (Including IPF)

Investigator

Gerard Criner, MD

Coordinator

Kriti Mittal, Elaina Budny, Rachel Nwafo

Visit clinicaltrials.gov for full description.

Contact

For more information about this trial or to inquire about eligibility, email [email protected] or call 215-707-1359.

Full Title

A Phase IIa/IIb, Randomised, Double Blind, Placebo-controlled, Parallel-group Dose-finding Study to Examine the Efficacy and Safety of BI 1839100 Administered Orally Over a 12-week Treatment Period in Patients With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis With Clinically Meaningful Cough